Teva to acquire Auspex for $3.2 billion
JERUSALEM and LA JOLLA, Calif. — Teva Pharmaceutical Industries Ltd. plans to purchase Auspex Pharmaceuticals Inc. in a deal valued at $3.2 billion. Teva said Monday that the agreement will bolster its core central nervous system (CNS) franchise with the addition of Auspex’s portfolio of medicines for people who live with movement disorders. A biopharmaceutical
